Ontology highlight
ABSTRACT:
SUBMITTER: Cadranel J
PROVIDER: S-EPMC5810621 | biostudies-literature | 2018 Jan
REPOSITORIES: biostudies-literature
Cadranel Jacques J Cortot Alexis B AB Lena Hervé H Mennecier Bertrand B Do Pascal P Dansin Eric E Mazieres Julien J Chouaid Christos C Perol Maurice M Barlesi Fabrice F Robinet Gilles G Friard Sylvie S Thiberville Luc L Audigier-Valette Clarisse C Vergnenegre Alain A Westeel Virginie V Slimane Khemaies K Buturuga Alexandru A Moro-Sibilot Denis D Besse Benjamin B
ERJ open research 20180101 1
Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (<i>ALK</i>) positive (<i>ALK</i><sup>+</sup>) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study included crizotinib-pretreated patients with advanced <i>ALK</i><sup>+</sup> or ROS proto-oncogene 1 positive (<i>ROS1</i><sup>+</sup>) tumours. Patients received oral ceritinib (750 mg·day<sup>-1</sup> as a starting dose) and best ...[more]